Elsevier

Neuroscience Letters

Volume 407, Issue 3, 30 October 2006, Pages 211-213
Neuroscience Letters

Decreased plasma adiponectin concentration in major depression

https://doi.org/10.1016/j.neulet.2006.08.043Get rights and content

Abstract

Adiponectin is the most abundant adipose-derived plasma protein. Recently adiponectin levels have been linked to most variables of metabolic syndrome and conventional risk factors for cardiovascular disease. However, its relation with major depression is yet unclear. We evaluated plasma adiponectin levels in 32 first-episode drug-naïve major depression (DSM-IV-TR) patients without conventional risk factors for cardiovascular disease and 32 matched healthy subjects. Major depression patients displayed lower adiponectin plasma levels compared to controls (P < 0.01). Adiponectin significantly correlated with depression severity, as assessed by HAM-D (rho = 0.83, P < 0.001). This study shows decreased plasma adiponectin concentrations in major depression patients and relates adiponectinemia reduction to major depression severity.

References (14)

There are more references available in the full text version of this article.

Cited by (93)

  • Cholesterol and triglyceride levels in first-episode patients with major depressive disorder: A meta-analysis of case-control studies

    2020, Journal of Affective Disorders
    Citation Excerpt :

    Of potential relevance, lipid profile disturbances are frequently observed in MDD, representing a major cardiovascular risk factor worldwide (Lemche et al., 2017). Specifically, MDD has been associated with lipid profile alterations in triglyceride, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, total cholesterol, leptin and adiponectin levels (Gowey et al., 2019; Kuwano et al., 2018; Leo et al., 2006; Liu et al., 2015; Oh and Kim, 2017; Skibinska et al., 2017). Although data indicates that lipid abnormalities may be related to socio-economic characteristics (Gowey et al., 2019; Vancampfort et al., 2013) and the metabolic adverse effects of medications (Hiles et al., 2016; Nyboe et al., 2016), it also can be features of MDD in the early phase.

View all citing articles on Scopus
View full text